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Abstract
Introduction
A major barrier for clinical trials in 
Alzheimer’s disease  is the lack of sen-
sitive clinical endpoints for the early 
stages. Until recently, regulatory agen-
cies have required demonstration of 
improvement in two disease domains, 
cognition plus functional or global sta-
tus, as the evidence of symptomatic 
improvement during clinical  trials 
for Alzheimer’s disease. However, the 
model of  Alzheimer’s disease pro-
gression indicates impairment in cog-
nition occurs earlier than changes in 
function and new draft guidance from 
the Food and Drug Administration 
considers change in cognition as an 
endpoint. The aim of this paper is to 
assess the outcomes of clinical trials 
in mild Alzheimer’s disease.
Short communication
The Alzheimer’s disease assessment 
scale – cognitive subscale  is the most 
widely used assessment of cognition 
in clinical trials; however, analysis of 
its psychometric properties, show it 
lacks the sensitivity to detect change 
in cognition in mild Alzheimer’s dis-
ease. There is a need to develop a new 
outcome measure capable of captur-
ing the subtle changes associated with 
mild AD in a reliable and valid way.
Conclusion
Given the heterogeneity of AD pheno-
types, development of a reliable, valid 
and clinically meaningful outcome 
measure is complex and challenging 
and will require discussion and co-
operation between researchers, clini-
cians, industry and patients and their 
advocates to achieve success.
Introduction
The pathological processes asso-
ciated with brain degeneration in 
Alzheimer’s disease (AD), such as 
amyloid deposition and the crea-
tion of neuroϐibrillary tangles, are 
known to occur before changes are 
observed in cognition and function in 
daily life.1,2 Major efforts are under-
way to ϐind disease modifying treat-
ments able to arrest these processes, 
and particularly, target the amyloid 
and tau pathways. Lack of success of 
new treatments in clinical trials has 
thus far been attributed to the need 
to intervene earlier in the disease 
process, and the absence of sensitive 
clinical endpoints in the early stages 
of AD.
Until recently, regulatory agen-
cies, the European Medicines Agency 
(EMA) and the Food and Drug 
Administration (FDA), have been 
reluctant to accept cognitive status 
alone as the primary endpoint for 
clinical trials in AD, preferring a com-
bination of cognition and function.3 
However, impairment of cognition 
occurs earlier than changes in func-
tion in daily life, and mild cognitive 
impairment is widely understood to 
have no notable effects on daily liv-
ing.4 The model of disease progres-
sion in AD implies that by the time 
changes in function begin to become 
evident, the primary pathological pro-
cesses are almost complete, and brain 
damage has become irreversible.1
The focus has thus moved to cog-
nitive outcomes in mild AD, and in 
recognition of the fact that functional 
improvements cannot be expected to 
be observed alongside improvement 
in cognition in mild AD, sympathy 
has recently been expressed by the 
FDA for using change in cognition as 
an endpoint, either as part of a com-
posite or alone.5 However, this raises 
a number of issues about the assess-
ment of outcome in mild AD, and 
there is a need for debate about these 
issues, and progress towards a con-
sensus view.
Short communication
The Alzheimer’s disease assessment 
scale – cognitive (ADAS-Cog) is the 
most widely used assessment of cog-
nition for clinical trials. The ADAS-
Cog is simple to administer and is rel-
atively brief, and this makes it attrac-
tive as an instrument for clinical 
 trials. It has thus become established 
as a gold standard for the assessment 
of cognition in AD and has been used 
as a primary endpoint in over 170 
clinical trials.
Over recent years, questions have 
been raised regarding the suitability 
of the ADAS-Cog to assess those with 
mild AD.6–8 These questions cover 
three main issues; the appropriate-
ness of the cognitive domains tested, 
the psychometric properties and 
the variability in administration and 
scoring of the ADAS-Cog.
The ADAS-Cog focuses on memory 
and language, but does not include 
tests of executive function, working 
memory and attention. This focus 
is reasonable in later stages of the 
disease, when there is a global dete-
rioration of cognition. However, in 
the early stages of the disease, there 
is now good evidence for different 
phenotypes of impairment, including 
distinct amnestic and dysexecutive 
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patterns.9 There is thus a need for 
assessment strategies that recognise 
the potential for individual differ-
ences in patterns of cognitive break-
down early in AD.
Early work on the psychomet-
ric properties of the ADAS-Cog was 
based on a small numbers of cases,10 
but later studies with larger samples 
indicated that the scale generally 
had satisfactory properties.11,12 Cano 
et al.13 evaluated the psychometric 
properties of both the individual 
components of the ADAS-Cog and the 
total score. Convergent validity with 
respect to Mini Mental Status Exam 
scores was satisfactory (0.63) and 
ADAS-Cog scores were not affected by 
age or gender. Test-retest and inter-
nal consistency reliability were also 
found to be high (0.93 and 0.84, 
respectively). ADAS-Cog total scores 
did not exhibit ϐloor or ceiling effects; 
however, when assessed at the indi-
vidual component level, 7 of the 11 
components demonstrated ϐloor or 
ceiling effects and skewed scores. 
Furthermore, component level ceiling 
effects were found to increase as the 
severity of AD decreased. Therefore, 
the ADAS-Cog may underestimate dif-
ferences in cognitive ability in those 
with mild to moderate AD, and this 
may limit the sensitivity of the ADAS-
Cog to the effects of interventions in 
mild AD.
Hobart et al.14 analysed the AD neu-
roimaging initiative data using Rasch 
analysis and found satisfactory ϐit to 
the model. The 11 item version repre-
sents a continuum on which cognitive 
performance can be measured and 
summing components to give a total 
score is acceptable. However, a sig-
niϐicant issue is that one of the sub-
scales (word recognition) that had 
the least evidence of ceiling effects 
showed poorest ϐit to the model. This 
suggests that a component that is 
useful in the assessment of mild AD 
may not be part of the continuum of 
cognitive impairment measured by 
the ADAS-Cog.
In addition to issues with the 
psychometric properties of the 
ADAS-Cog, there also appears to be 
variability in the administration and 
scoring methods employed.15 More 
recently, Schafer et al.16 found 58 
out of 70 experienced raters made 
errors when scoring the ADAS-Cog. 
Doraiswamy et al.12 also report a con-
siderable amount of measurement 
error which may have arisen from 
factors such as patient frustration, 
incorrect scoring or distraction dur-
ing testing. Variability in administra-
tion methods and errors in scoring 
have the potential to undermine the 
results of multi-centre clinical  trials 
and these are issues that warrant 
careful monitoring.
The neuropsychological test bat-
tery (NTB)17 has recently been added 
as a candidate primary efϐicacy meas-
ure by the EMA. Research evidence 
suggests that the NTB is superior to 
the ADAS-Cog, in particular, its abil-
ity to detect reduced impairment as 
a result of treatment in a sample of 
people with mild AD. The increased 
sensitivity of the NTB to detect 
change would allow smaller  sample 
sizes to be used in future clinical 
trials. However, the NTB’s focus on 
memory and executive function, 
mean additional tests are required 
for a targeted assessment of relevant 
cognitive functions.
Support has been expressed for 
adapting existing tools such as the 
ADAS-Cog to measure mild AD.14 
Although this is attractive in main-
taining the status quo, we believe that 
it may be misconceived, and that tools 
designed for the later stages of the 
disease are a poor starting point for 
assessment of mild AD. As mentioned 
above, the clinical effects of mild AD 
are different from the later stages of 
the disease. The assessment of out-
comes is currently an active area 
of AD research and much has been 
done to capitalise on advances in 
technology to improve the accuracy 
and  sensitivity of measures. Recent 
discussions have highlighted these 
emerging assessment methods, but as 
yet, no conclusions have been reached 
as to which test or combination of 
tests would be capable of capturing 
the subtle changes in cognition and 
function associated with early AD in 
a reliable and valid way.
Discussion
There is an urgent need to take stock, 
and consider issues underlying cog-
nitive endpoints for clinical trials in 
mild AD and develop a new outcome 
measure that is modelled on and 
reϐlects the clinical experience of the 
patient in the early stages of AD.
Questions that need to be 
addressed include the ‘what’, and the 
‘how’ of assessment of cognitive out-
comes. A number of issues pertaining 
to the ‘what’ of assessment require 
debate and resolution:
• Is the idea of isolated cogni-
tive endpoints acceptable to 
all stakeholders, and can this 
have a meaningful clinical 
correlation?
• Should the focus be solely on 
areas of cognition that change 
early in the disease, or should 
assessment seek to be more 
comprehensive?
• How can different phenotypes 
of early cognitive impairment 
be accommodated?
• Should the assessment seek to 
judge the importance of dif-
ferent aspects of cognition, or 
does cognition serve simply as 
a surrogate marker of disease 
progress?
• What is of clinical relevance to 
a patient with early AD?
• Questions concerning the 
‘how’ of assessment also 
abound, and put practical con-
straints on ‘what’ is assessed:
• Should assessment be primar-
ily through objectively scored 
tests or are subjective rater 
judgement scales the pre-
ferred model?
• What are the practical con-
straints on the length of 
assessment, and other proce-
dural aspects?
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• How will the inϐluence of edu-
cation level and general ability 
on cognition be allowed for in 
assessment?
What constraints are imposed by 
practice effects when attempting to 
detect decline in cognition?
Conclusion
Given the acknowledged inadequacy 
of current outcome measures and the 
new FDA guidance, there is a need 
to develop a new outcome meas-
ure capable of capturing the subtle 
changes in cognition and function 
associated with mild AD, in a  reliable 
and valid way. To develop a reli-
able, valid and clinically meaningful 
outcome measure is complex and 
challenging. Consultation between 
researchers, clinicians, industry and 
patients and their advocates is essen-
tial to achieving success.
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